

News Article downloaded from - <http://www.bioportfolio.com> on Monday, November 23, 2009

Read [European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel\(R\) for Patients With Moderate-to-Severe Psoriasis](http://www.bioportfolio.com/news/European_Commission_Announces_Marketing.html) on BioPortfolio.com

(http://www.bioportfolio.com/news/European_Commission_Announces_Marketing.html)

European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel(R) for Patients With Moderate-to-Severe Psoriasis

Wednesday 9th of July 2008 5:00

BioPortfolio no longer holds the full text of this article in PDF form.

[Click Here To Read BioPortfolio's Web Page on European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel\(R\) for Patients With Moderate-to-Severe Psoriasis](http://www.bioportfolio.com/news/European_Commission_Announces_Marketing.html)

Above results from a Google Custom Search Engine. [Search on BioPortfolio](#)

Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

